In a talk at the recent HemOnc Today’s Melanoma and Cutaneous Malignancies meeting, Christian Blank, group leader of the division of immunology at Netherlands Cancer Institute, presented his views of checkpoint blocking therapies. He concluded that targeted therapy is not enough to fight melanoma.
Publications
Immunotherapy Combinations Coming to the Forefront in Melanoma
PD-1/PD-L1 should be the backbone of melanoma treatment for many patients, says Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine.
Taking on melanoma, one cell at a time
Single-cell analysis is a groundbreaking approach now being used across biological fields to explore a common problem: how to study cellular diversity in cell environments with heterogeneous populations. Such diversity can have profound implications for cell survival and proliferation, response to drug therapies and interventions, as well as myriad other biological processes.
MC1R Variant Independently Linked With Melanoma
People who are carriers of two variants of melanocortin-1 receptor (MC1R), a gene that regulates pigmentation, were at increased risk for melanoma regardless of previous UV radiation exposure, according to the results of a study published in JAMA Dermatology.